Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Pharma Outsourcing

The search for a cure for cancer unites three partnerships between a drug developer and a pharmaceutical chemical company

by Assistant Managing Editor Michael McCoy and Associate Editor Lisa M. Jarvis
April 10, 2006 | A version of this story appeared in Volume 84, Issue 15

Reflections
[+]Enlarge
Credit: Scynexis Photo
Chemist Annette Shaw works up a reaction in Scynexis' Research Triangle Park laboratories.
Credit: Scynexis Photo
Chemist Annette Shaw works up a reaction in Scynexis' Research Triangle Park laboratories.

COVER STORY

Pharma Outsourcing

The advertisements in popular magazines would convince most readers that the pharmaceutical industry is ruled by giant multinational companies focused exclusively on "lifestyle" drugs to fix problems that could be cured through more healthful living.

In fact, much pharmaceutical research is conducted by small companies that many magazine readers have never heard of. And many of the industry's research dollars are spent confronting serious afflictions such as cancer, heart disease, pain, and infection. For example, in the U.S. last year there were 399 drugs in development to treat cancer and 146 for heart disease and stroke, according to Pharmaceutical Research & Manufacturers of America.

Two of the drugs are still in development, and if history is any guide, one or both of them will fail for one reason or another. Drug development is a high-risk business, but the stories of the scientists who discover and synthesize such compounds are always compelling.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.